<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064090</url>
  </required_header>
  <id_info>
    <org_study_id>VION-CLI-032</org_study_id>
    <secondary_id>CDR0000306465</secondary_id>
    <secondary_id>MDA-DM-030096</secondary_id>
    <nct_id>NCT00064090</nct_id>
  </id_info>
  <brief_title>3-AP and Cytarabine in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>A Phase I Study of Triapine and Cytarabine in Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer&#xD;
      cells from dividing so they stop growing or die. 3-AP may stop the growth of cancer cells by&#xD;
      blocking the enzymes necessary for cancer cell growth and may help cytarabine kill more&#xD;
      cancer cells by making them more sensitive to the drug.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining cytarabine with 3-AP in&#xD;
      treating patients who have relapsed or refractory hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility, tolerability, and toxic effects of 3-AP in combination with&#xD;
           cytarabine in patients with hematologic malignancies.&#xD;
&#xD;
        -  Determine the maximum tolerated dose and phase II dose of cytarabine in this regimen in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the biological effects of 3-AP and its interaction with cytarabine in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a pilot, dose-escalation study of cytarabine.&#xD;
&#xD;
      Patients receive 3-AP IV over 6 hours followed by cytarabine IV over 18 hours on days 1-5.&#xD;
      Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients achieving a response may receive an additional course as&#xD;
      consolidation therapy.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of cytarabine until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD is determined, an additional 10&#xD;
      patients receive treatment at that dose.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 20-25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following hematologic malignancies:&#xD;
&#xD;
               -  Acute myeloid leukemia&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML)&#xD;
&#xD;
               -  CML in blast crisis&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
               -  High-risk* myelodysplastic syndromes, including the following:&#xD;
&#xD;
                    -  Refractory anemia with excess blasts (RAEB)&#xD;
&#xD;
                    -  RAEB in transformation&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia NOTE: *High-risk myelodysplasia defined as&#xD;
                       having an International Performance Scoring System score of at least 1.5,&#xD;
                       based on adverse cytogenetics, greater than 10% blasts in marrow, and&#xD;
                       cytopenias in at least 2 lineages&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
          -  Ineligible for higher priority protocols&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 2 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL (unless considered due to malignancy)&#xD;
&#xD;
          -  ALT or AST no greater than 3 times upper limit of normal&#xD;
&#xD;
          -  Chronic hepatitis allowed&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL (unless considered due to malignancy)&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No arrhythmias (other than atrial fibrillation or flutter) requiring treatment&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Concurrent infections under active treatment with and controlled by antibiotics&#xD;
             allowed&#xD;
&#xD;
          -  No other concurrent life-threatening illness&#xD;
&#xD;
          -  No mental deficit or psychiatric history that would preclude giving informed consent&#xD;
             or complying with protocol&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 1 week since prior growth factors, including the following:&#xD;
&#xD;
               -  Epoetin alfa&#xD;
&#xD;
               -  Filgrastim (G-CSF)&#xD;
&#xD;
               -  Sargramostim (GM-CSF)&#xD;
&#xD;
               -  Interleukin-3&#xD;
&#xD;
               -  Interleukin-11&#xD;
&#xD;
          -  No concurrent anticancer immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 72 hours since prior hydroxyurea&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent anticancer radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive cytotoxic agents (in the absence of&#xD;
             rapidly progressing disease)&#xD;
&#xD;
          -  At least 1 week since prior nonmyelosuppressive therapy&#xD;
&#xD;
          -  No other concurrent standard or investigational therapy for the malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Sznol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

